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Abstract
Objective—To determine the percentage of children with nonalcoholic fatty liver disease 
(NAFLD) in whom intervention for low density lipoprotein-cholesterol (LDL-C) or triglycerides 
(TG) was indicated based upon National Heart, Lung, and Blood Institute (NHLBI) guidelines.
Corresponding Author: Jeffrey B. Schwimmer, M.D., Director, Fatty Liver Clinic, Department of Pediatrics, UC San Diego, 3020 
Children’s Way, MC 5030 San Diego, CA 92123, jschwimmer@ucsd.edu, phone: 858-966-8907, fax: 858-560-6798.
*List of additional members of the Nonalcoholic Steatohepatitis Clinical Research Network is available at www.jpeds.com 
(Appendix).
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
The authors declare no conflicts of interest.
Portions of this study were presented as an abstract at the World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, 
Montreal, Quebec, October 5–8 2016.
HHS Public Access
Author manuscript
J Pediatr. Author manuscript; available in PMC 2019 July 01.
Published in final edited form as:
J Pediatr. 2018 July ; 198: 76–83.e2. doi:10.1016/j.jpeds.2018.02.038.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Study design—Multi-center, longitudinal cohort study of children with NAFLD enrolled in the 
NIDDK Nonalcoholic Steatohepatitis Clinical Research Network. Fasting lipid profiles were 
obtained at diagnosis. Standardized dietary recommendations were provided. After 1 year, lipid 
profiles were repeated and interpreted according to NHLBI Expert Panel on Integrated Guidelines 
for Cardiovascular Health and Risk Reduction. Main outcomes were meeting criteria for clinically 
actionable dyslipidemia at baseline, and either achieving lipid goal at follow up or meeting criteria 
for ongoing intervention.
Results—There were 585 participants, mean age 12.8 years. Prevalence of children warranting 
intervention for LDL-C at baseline was 14%. After 1 year of recommended dietary changes, 51% 
achieved goal LDL-C, 27% qualified for enhanced dietary and lifestyle modifications, and 22% 
met criteria for pharmacologic intervention. Elevated TG were more prevalent, with 51% meeting 
criteria for intervention. At 1 year, 25% achieved goal TG with diet and lifestyle changes, 38% 
met criteria for advanced dietary modifications, and 37% qualified for antihyperlipidemic 
medications.
Conclusion—Over half of children with NAFLD met intervention thresholds for dyslipidemia. 
Based on the burden of clinically relevant dyslipidemia, lipid screening in children with NAFLD is 
warranted. Clinicians caring for children with NAFLD should be trained in lipid management.
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Atherosclerotic coronary artery disease is the primary cause of mortality in adults in the 
United States, and is responsible for nearly 400,000 deaths annually.1 The process of 
atherosclerosis begins in childhood and is associated with dyslipidemia.2,3 Therefore, both 
the American Academy of Pediatrics and the American Heart Association recommend 
identifying children at risk for premature cardiovascular disease. In 2011, the revised 
National Heart, Lung, and Blood Institute (NHLBI) Expert Panel on Integrated Guidelines 
for Cardiovascular Health and Risk Reduction4 reinforced the importance of lipid screening 
in childhood and provided a pathway for lifestyle and pharmacologic interventions. In 
addition, they identified subgroups requiring specialized attention but did not address 
children with nonalcoholic fatty liver disease (NAFLD).
NAFLD is an emerging clinical problem in children and adolescents. With an estimated 
9.6% prevalence, NAFLD is the most common cause of chronic liver disease in children,5 
and the leading cause of liver transplantation in young adults.6,7,8 Cardiovascular disease is a 
serious extra-hepatic comorbidity in patients with NAFLD, and is the most common cause 
of death in adults with this condition.9,10,11 In children, NAFLD is also associated with 
multiple cardiovascular risk factors such as obesity, insulin resistance, hypertension, and 
dyslipidemia.12,13,14 Recent pediatric NAFLD guidelines include monitoring of lipids.15 
However, the treatment of hypercholesterolemia and/or hypertriglyceridemia in children 
with NAFLD has not been addressed. Thus it is unknown how many children with NAFLD 
require intervention for dyslipidemia. Moreover, there are no longitudinal data on lipids in 
children with NAFLD in response to intervention. Therefore, the primary study aim was to 
apply the NHLBI guidelines to children with NAFLD. Specific goals were to determine the 
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frequency of clinical intervention needed for elevated plasma low density lipoprotein (LDL-
C) or triglycerides (TG) and the outcomes on lipid profiles following one year of dietary 
standard of care.
METHODS
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NASH 
Clinical Research Network (NASH CRN) enrolled children in longitudinal cohort studies 
(Database and Database 2; NCT01061684) and clinical trials (TONIC; NCT00063635 and 
CyNCh; NCT01529268). These studies have been described16,17 and were performed at 
each participating pediatric clinical center across the United States (see appendix). The 
studies were approved by the institutional review boards at the participating institutions. 
Written, informed consent was obtained from a parent or guardian for all participants, and 
written assent was obtained from children. For this analysis, we included children who were 
ages 9–18 years with biopsy-confirmed NAFLD. Those without weight, height, blood 
pressure, or fasting lipid panels measured at the initial study visit were excluded from this 
analysis. Those who were already taking a statin, fibrate, or omega-3 fish oil at the time of 
enrollment in the study, or those who were subsequently prescribed one of these medications 
prior to 48 week follow up were excluded from the application of the guidelines as well.
Age and sex were recorded for all participants. The following medical background was 
obtained in all study participants: presence of diabetes mellitus type I and type II, chronic 
inflammatory disease (such as juvenile rheumatoid arthritis or lupus), renal disease and 
dysfunction, HIV status, organ transplant, and the use of any lipid lowering medications in 
the preceding 6 months.
Physical measurements included height, weight, systolic and diastolic blood pressures. Body 
mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Blood 
pressure percentiles were computed according to The Fourth Report on the Diagnosis, 
Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.18 At the 
initial visit, fasting laboratory assays included total cholesterol (TC), high-density 
lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and 
triglycerides (TG). All laboratory studies were repeated at the 48 week follow-up.
A diagnosis of NAFLD was based on liver histology with at least 5% of hepatocytes 
containing macrovesicular fat, and exclusion of other causes of liver disease based upon 
clinical history, laboratory studies, and histology. Biopsy specimens were stained with 
hematoxylin-eosin and Masson’s trichrome stains, and reviewed and scored by the 
Pathology Committee of the NASH CRN according to the NASH CRN scoring system.19 
Liver biopsies were diagnosed as NASH, borderline NASH, or NAFLD without NASH 
based upon the aggregate presence and degree of the individual features of NAFLD. The 
diagnosis of NASH, borderline NASH, or NAFLD was made as a consensus agreement of 
the NASH CRN pathology committee.
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NHLBI Guidelines
The 2011 revised NHLBI guidelines were applied to our study cohort. Normal plasma lipid 
levels in children were defined based upon The National Cholesterol Education Program 
(NCEP) Expert Panel on Cholesterol levels in Children.20 The NHLBI guidelines provide a 
separate decision-tree for LDL-C and TG in order to determine the specific intervention 
required, based upon the degree of lipid derangement (Figures 1 and 2). By following the 
NHLBI algorithms, children who met thresholds for clinically actionable dyslipidemia were 
identified at baseline as being in the Target LDL-C or the Target TG group.
The Target LDL-C pathway was applied to those with baseline plasma LDL-C >130 mg/dL. 
After receiving dietary counseling, similar to that of the Cardiovascular Health Integrated 
Lifestyle Diet (CHILD-1) as described in the algorithm (online), a repeat fasting lipid 
profile was obtained at one year follow up. Taking into consideration the presence of high 
and moderate-risk factors (online), combined with the degree to which LDL-C remained 
elevated, children who did not achieve goal LDL-C would meet criteria for consideration of 
statin therapy or the intensification of a lipid-specific diet (online). The Target TG pathway 
was applied to children with baseline plasma TG with age specific cutoffs > 100 mg/dL for 
children < 10 years, and >130 mg/dL for children 10 years and older. In a similar fashion, 
children received dietary counseling and fasting lipid profiles were obtained at one year 
follow up. In children who did not achieve their goal TG, the guidelines provide instructions 
for initiation of the CHILD 2-TG diet (online) or the consideration of pharmacotherapy.
NASH CRN Standard of Care
The NASH CRN Standards of Care Committee developed a uniform set of practices to be 
applied by investigators in the NASH CRN to the care of pediatric patients with NAFLD. 
Recommendations for dietary counseling were based upon guidelines from the USDA; 
specifically, limiting percent of daily caloric intake from saturated fatty acids to < 10%, 
replacing these with mono and polyunsaturated fatty acids, and limiting dietary cholesterol 
intake to <300 mg.21 These recommendations were consistent with those outlined in the 
CHILD-1 diet in the NHLBI guidelines. However, the individual application of these 
recommendations and the specifics of caloric and cholesterol intake were not monitored by 
each participating site.
Statistical analyses
The demographic and clinical characteristics of all children included in this study were 
reported using standard descriptive statistics. Medians and ranges were reported for 
continuous variables and counts and percentages were given for categorical variables. 
Following the NHLBI guidelines for management of dyslipidemia in children, we calculated 
the frequency of actionable cases as patients flowed through the NHLBI branch-tree 
algorithm. Two separate algorithms were used to define dyslipidemia targeting LDL-C and 
TG levels independently. Subjects already on statins, fibrates, or omega-3 fish oil were 
excluded from analysis.
Study participants were pooled from four distinct NASH CRN protocols. Sensitivity 
analyses were performed to determine whether lipid levels at enrollment or follow up varied 
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between protocols. R version 3.3.2 software (The R Foundation for Statistical Computing, 
Vienna, Austria) was used for all analyses.
RESULTS
There were 669 children enrolled in the NASH CRN, of whom 3 were excluded for missing 
data, 3 were excluded because they did not have NAFLD, and 40 were excluded because 
they were < 9 years of age. Thus, 623 children with NAFLD ages 9–18 were evaluated in 
this study; 25 were receiving pharmacologic intervention (statin, n =10; fish oil, n =15). 
During the course of the investigation, prior to the week 48 evaluation, an additional 13 
children were prescribed antihyperlipidemic medications (statin, n=6; fish oil, n=7). 
Therefore, there were 585 children with NAFLD not taking antihyperlipidemic medications 
evaluated for their response to standard of care intervention at both baseline and 48 weeks. 
Demographic and clinical characteristics for these 585 children are shown in Tables 1 and 2. 
There was a male predominance of 72% (n=419) in our group. The mean age for all subjects 
was 12.8 (SD 2.4) years, and BMI 32.6 (SD 6.5) kg/m2. In the cohort, the median LDL-C 
was 97 (19, 212) mg/dL, and the median triglyceride concentration was 133 (18, 726) 
mg/dL. Using the NHLBI guidelines, 4% (n= 24) of participants met criteria for the target 
LDL-C pathway alone and 41% (n=239) met criteria for the TG pathway alone. An 
additional 10% (n= 60) of participants had lipid profiles that qualified them for both target 
pathways. The remaining 45% (n=262) did not qualify for either pathway.
LDL-cholesterol
As shown in Figure 1, 14% (n=84) of our study participants had levels that met criteria for 
intervention in the Target LDL-C pathway. The median LDL-C of those targeted was 145 
(131, 212) mg/dL. After one year, fasting lipid panels were available for 78 participants with 
targeted LDL-C. Of these, 51% (n= 40) achieved goal levels as shown in Figure 1, Box A. 
Achieving goal level of LDL-C at one year follow up was significantly associated with a 
decrease in BMI Z-score compared with those that did not meet goal (−0.07 (−0.91, 0.13) 
vs. 0.01 (−0.34, 0.31), p= 0.018). Additionally, achieving goal LDL-C at follow up was also 
significantly associated with a decrease in ALT compared with those not achieving goal 
(−57 (−242, 126) vs. 0 (−223, 203), p=0.003)
An additional 27% (n=21) of participants with targeted LDL-C met criteria for enhanced 
dietary modifications with a lipid-specific diet (Figure 1, Box B). As shown in Figure 1,, 
application of the guidelines including risk factors (as shown in supplemental data) shows 
that 22% (n= 17) of those originally with targeted LDL-C met criteria for statin at 1 year. 
Thus, the combination of children already taking a statin at baseline or reaching criteria for 
initiation of a statin at one year represented 5.3% (33/623) of the entire cohort.
Triglycerides
As shown in Figure 2, 51% (n=299) of the cohort met criteria for intervention in the Target 
Triglyceride pathway. The median triglyceride concentration of those targeted was 138 (38, 
330) mg/dL in children <10 years and 147 (20, 727) mg/dL for those 10–18 years. Three 
participants (0.5%) had baseline triglyceride concentrations that warranted referral to a lipid 
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specialist as shown in Figure 2, Box A. After one year, fasting lipid panels were available for 
289 participants with targeted triglycerides. Of these, 25% (n=73) achieved goal triglyceride 
levels as shown in Figure 2, Box B. Achieving goal TG at one year follow up was associated 
with a significantly greater decrease in BMI Z-score compared with those that did not 
achieve goal levels of TG (−0.08 (−1.37, 0.24) vs. −0.02 (−1.42, 0.39), p= 0.033). There 
were no significant differences between groups with respect to change in ALT (−15 (−305, 
642) vs. −16 (−416, 203), p= 0.958
However, the large majority of subjects met criteria for continued interventions at one year; 
38% (n=110) had triglyceride levels between 130–199 mg/dL, and thus warranted 
intensification of the CHILD-2- TG diet as shown in Figure 2, Box C. There were 36% 
(n=104) of participants that met criteria for antihyperlipidemic medications as shown in 
Figure 2, Box D.
Lipid values and histology
As shown in Table 1, there was no significant difference in meeting criteria for target LDL-
C, TG, both, or neither by fibrosis stage (p= 0.098) or diagnosis of NASH (p= 0.334)
Sensitivity analysis
In both sets of sensitivity analysis, the percent of participants from each of the four studies 
meeting criteria for application of the LDL and TG algorithms was not statistically 
significant (P = .094 and p=0.341, respectively). Furthermore, comparison between the 4 
groups and the percentages of those achieving various LDL and TG-related outcomes also 
did not differ statistically (p= 0.484 and p= 0.787, respectively).
DISCUSSION
We studied the prevalence of clinically relevant lipid derangement in a large, multicenter 
cohort of children with NAFLD from pediatric centers across the United States. Two thirds 
of the cohort met criteria for intervention based on either LDL-C or TG elevation. 
Abnormalities in TG concentration was the more common lipid derangement. Following one 
year of care, approximately half of children in the target LDL-C group and one fourth of 
children in the target TG group reached the recommended lipid level as per the NHLBI 
guidelines. Thus, a substantial number of participants, despite receiving standard of care 
recommendations, met criteria for additional therapeutic intervention in the form of nutrition 
and/or medication. Approximately 30% of children in the target LDL-C group and 40% of 
children in the target TG group met thresholds for a lipid-specific CHILD-2 diet and 
continued lipid monitoring. Furthermore, one fifth of the cohort with targeted LDL-C and 
close to 40% of participants with targeted TG met criteria for consideration of 
antihyperlipidemic medications.
In children with NAFLD, there is a higher prevalence of clinically actionable dyslipidemia 
than in the general population. Based upon data from NHANES 1999–2012, 6.5% of 
adolescents aged 12–17 years in the general population met target LDL-C values compared 
with 15% of our cohort of children with NAFLD.22 Notably, our study included longitudinal 
data and demonstrated that 5.3% of the children with NAFLD in our cohort were either 
Harlow et al. Page 6
J Pediatr. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
already prescribed or reached criteria for use of a statin at follow up. There are no available 
longitudinal data for comparison. However, using cross-sectional data only, indications for 
statin use were met in less than 1% of adolescents ages 12–17 and up to 2.5% of youths 17–
21 years in the general population.23 Furthermore, the prevalence of hypertriglyceridemia 
meeting target TG levels is 12% in the general population24 and 25% in children with 
obesity.25, 26 Thus the fact that 51% of our cohort of children with NAFLD had target TG 
levels necessitating intervention and indicates the clinical relevance of dyslipidemia in 
pediatric NAFLD. Based upon these findings, lipid screening is warranted in all children 
with NAFLD.
Children with NAFLD and dyslipidemia should be considered to be at increased risk for 
premature cardiovascular disease. The association between NAFLD and dyslipidemia in 
children has been shown to be strong and independent of weight.13, 27 In NAFLD, the 
predominant pattern observed is combined dyslipidemia; characterized by an elevation in 
LDL-C, TG, and a decrease in HDL-C.28 Combined dyslipidemia is highly atherogenic and 
predictive of future cardiovascular disease.29, 30 Notably, atherosclerosis is a progressive 
process that begins in childhood31, 32 and is associated with dyslipidemia.33, 34 In addition to 
dyslipidemia, NAFLD itself may increase the risk of atherosclerosis. In an autopsy study of 
children ages 2 to 19 years the prevalence of atherosclerosis was increased by a factor of 2 in 
those children with NAFLD.35 In children with NAFLD, carotid intimal media thickness has 
been shown to be greater than in matched controls, i.e. children with obesity but without 
NAFLD.36, 37, 38 Therefore, although coronary artery disease and stroke tend to be 
conditions of later adulthood, this evidence suggests that children with NAFLD may be at an 
increased risk of cardiovascular morbidity and mortality, perhaps at a younger age than the 
general population. Screening for dyslipidemia in childhood, as recommended by the 
NHLBI guidelines, allows for both early detection of cardiovascular disease risk and the 
potential for intervention.
The management of dyslipidemia in children is rooted in nutritional intervention. In a 
randomized controlled, multi-center trial of children with dyslipidemia, the Dietary 
Intervention Study in Children (DISC), dietary counseling by a registered nutritionist 
produced a significant reduction in intake of saturated fats and cholesterol. This resulted in a 
reduction of plasma LDL-C compared with those who received routine educational materials 
on heart-healthy diet. These findings were sustained over 3 years.39 In the present study, the 
initiation of a CHILD-2 TG or LDL-C specific diet was the most common intervention 
required. With standard of care dietary recommendations, half of the targeted LDL-C cohort 
and one fourth of the targeted TG cohort achieved their lipid goals at one year follow up. 
However, a substantial percentage of those with targeted lipid levels met criteria for ongoing 
nutritional intervention. Although it was not known how many children had their counseling 
done by a physician versus a registered dietician, prior studies have shown that dietary 
education from a registered dietician can be more effective for long term LDL-C reduction.
40
 Nonetheless, pediatric gastroenterologists have identified inadequate access to registered 
dieticians and lack of insurance coverage for such referrals as substantial barriers to care.41 
Therefore, strong consideration should be given to making access to a registered dietician a 
standard part of care in children with NAFLD.
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Statins are the mainstay of therapy for individuals in whom dietary interventions fail to 
achieve goal LDL-C levels and should also be considered for cardiovascular risk reduction 
even in patients with NAFLD. However, given their potential adverse effect profile, these 
medications are often under-utilized. It is known that statins may cause elevations in serum 
aminotransferases42, and are thus often avoided in patients with elevated aminotransferases 
or preexisting liver disease. The AASLD practice guidelines concluded that in adults “statins 
are safe in patients with liver disease and there is no evidence that patients with chronic liver 
disease including NAFLD and NASH are at higher risk for serious liver injury than those 
without liver disease.”43 In children, the prevailing data on the efficacy and safety of statin 
use has been in the population with familial hypercholesterolemia. In a meta-analysis of 
these studies, statins were shown to be efficacious for lipid lowering and were not associated 
with an increased risk of liver-related adverse events.44 However, there is a gap in 
knowledge regarding efficacy and safety in children with underlying liver disease, such as 
NAFLD. Although the NHLBI guidelines recommend their use in adverse lipid profiles 
refractory to diet and lifestyle changes, additional studies on the long term benefits and 
safety of statins in children with NAFLD would be beneficial.
A strength of this study includes a large, multi-center cohort that was broadly representative 
of children with clinical NAFLD. Subjects were recruited by the NASH CRN, which has 
geographic diversity as well as a detailed, rigorous protocol to phenotype the cohort. 
Furthermore, the longitudinal nature of this study adds novel information about the 
treatment of hypercholesterolemia and hypertriglyceridemia in children with NAFLD 
including how interventions such as dietary modifications influence this over time. Our 
study had excellent retention at 48 week follow up.
A limitation of this study is that although recommendations in the standard of care 
documents on daily caloric intake from saturated fatty acids and cholesterol were similar to 
those in the NHLBI guidelines, they were not identical. Furthermore, the individual 
counseling provided by physicians versus registered dieticians at study sites was not 
monitored, and specific recommendations were undocumented. Although all participants 
received some form of dietary counseling, it is possible that there may be variation between 
study sites in terms of specific counseling that was offered. Although a lack of rigid control 
in the dietary implementation limited the homogeneity of response, the implementation 
across centers is more reflective of the real world and thus is likely to be a more 
generalizable result with respect to the rates of change in this patient population. 
Additionally, we may have under-estimated children with hypercholesterolemia who would 
meet criteria for consideration of medication, based on incomplete family history of CVD. 
Lastly, our study evaluated children ages 9–18, as this is the recommended age for universal 
screening of lipids, per the NHLBI guidelines. However, this highlights a gap in the 
knowledge about the cardiovascular risk in younger children with NAFLD, and future 
studies are needed to better evaluate this age group.
In summary, NAFLD is a common clinical problem that is frequently associated with 
clinically actionable dyslipidemia. Targeted dietary interventions can be effective for a 
subset of this population. The number of children who will require more aggressive 
intervention including medications is substantial. This strongly supports the new pediatric 
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NAFLD guidelines15 and merits consideration of pediatric NAFLD as a risk factor for 
clinically significant dyslipidemia in future pediatric lipid guidelines. Future studies should 
prospectively address safety of statin usage specifically in children with NAFLD and 
identify optimal levels of LDL-C and triglycerides to reduce cardiovascular disease risk in 
children with NAFLD.
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Table 3
Cardiovascular Health Integrated Lifestyle Diet (CHILD-1)
2–21 years
Primary beverage: Fat-free unflavored milk
Limit/avoid sugar-sweetened beverages; encourage water
Fat content:
• Total fat 25–30% of daily kcal/EER
• Saturated fat 8–10% of daily kcal/EER
• Avoid trans fat as much as possible
• Cholesterol < 300 mg/d
Encourage high dietary fiber intake from foods. Naturally fiber-rich foods are recommended (fruits, vegetables, 
whole grains); fiber supplements are not advised. Limit refined carbohydrates (sugars, white rice, white bread).
Supportive actions:
• Teach portions based on EER for age/gender/activity
• Encourage moderately increased energy intake during periods of rapid growth and/or 
regular moderate-to-vigorous physical activity
• Encourage dietary fiber from foods: Age plus 5 g/d
• Limit naturally sweetened juice (no added sugar) to 4 oz/d
• Limit sodium intake
• Support DASH-style eating plan
Table 4
Risk factor definitions for dyslipidemia algorithm
Definition
Family History myocardial infarction, angina, coronary artery bypass graft/stent/angioplasty, sudden 
cardiac death in parent, grandparent, aunt, or uncle male < 55 years, female <65 years
High Level Risk Factors
Hypertension requiring drug therapy (BP > 99th percentile+ 5mmHg)
Current cigarette smoker
BMI > 97th percentile
Presence of high risk 
conditions
Diabetes mellitus type I and II, chronic renal disease/ end stage renal disease/ post renal 
transplant, post orthotopic heart transplant, Kawasaki disease with current aneurysms
Moderate Level Risk 
Factors
Hypertension not requiring drug therapy
BMI > 95th and < 97th percentile
HDL-C < 40 mg/dL
Presence of moderate 
risk conditions
Kawasaki disease with regressed coronary aneurysms, chronic inflammatory disease 
(systemic lupus erythematosus, juvenile rheumatoid arthritis), Human immunodeficiency 
virus, nephrotic syndrome
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Table 5
Cardiovascular Health Integrated Lifestyle Diet, LDL-C and TG specific (CHILD-2)
Elevated LDL-C: CHILD 2-LDL
2–21 years
Refer to a registered dietician for family medical nutrition therapy
• 25–30% of daily calories from fat, ≤ 7% from saturated fat, ~ 10% from monounsaturated fat
• < 200 mg/dL of cholesterol
• Avoid trans fats as much as possible
Supportive actions
• Plant sterol esters and/or plant stanol esters* up to 2 g/d as replacement for usual fat sources can be used after 
age 2 years in children with familial hypercholesterolemia.
• Plant stanol esters as part of a regular diet are marketed directly to the public. Short-term studies show no 
harmful effects in healthy children.
• The water-soluble fiber psyllium can be added to a low-fat, low saturated fat diet as cereal enriched with 
psyllium at a dose of 6 g/d for children 2–12 years, and 12 g/d for those ≥ 12 years.
• As in all children, 1 hour/day (h/d) of moderate-to-vigorous physical activity and < 2 h/d of sedentary screen 
time are recommended.
Elevated TG: CHILD 2-TG
2–21 years
Refer to a registered dietician for family medical nutrition therapy
• 25–30% of daily calories from fat, ≤ 7% from saturated fat, ~ 10% from monounsaturated fat
• < 200 mg/dL of cholesterol
• Avoid trans fats as much as possible
Decrease sugar intake
• Replace simple with complex carbohydrates
• No sugar-sweetened beverages
Increase dietary fish to increase omega-3 fatty acids
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Figure 1. 
The NHLBI guideline for elevated LDL-C. This algorithm and the superimposed numbers 
show the participants that met criteria for actionable LDL-C and after dietary interventions, 
those at follow up who met criteria for statin therapy, dietary intensification, or those that 
met goals.
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Figure 2. 
The NHLBI guideline for elevated TG. This algorithm and the superimposed numbers show 
the participants that met criteria for actionable TG and after dietary interventions, those at 
follow up who met criteria for consideration of medications, dietary intensification, or those 
that met goals.
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Table 2
Follow up demographic, laboratory, and clinical characteristics among children with NAFLD
Variables
N (%) or median (range)
Target LDL-C only
N=24
Target TG only
N= 239
Target both
N= 60
BMI (kg/m2) 33 (23, 50) 34 (19, 64) 33 (24, 65)
BMI Z-score 2.3 (1.5, 2.8) 2.4 (0.6, 3.4) 2.3 (1.2, 2.8)
SBP (mm Hg) 124 (95, 166) 124 (93, 162) 125 (97, 153)
DBP (mm Hg) 69 (48, 85) 69 (49, 99) 68 (52, 99)
LDL-C (mg/dL) 128 (85, 209) 97 (27, 178) 131 (73, 189)
HDL-C (mg/dL) 39 (27, 66) 35 (19, 66) 35 (19, 58)
Total cholesterol (mg/dL) 189 (139, 275) 166 (81, 271) 213 (124, 286)
TG (mg/dL) 124 (44, 381) 159 (44, 514) 213 (80, 709)
AST (U/L) 57 (SD 59) 55 (SD 42) 62 (SD 55)
ALT (U/L) 93 (SD 101) 94 (SD 86) 110 (SD 97)
GGT (U/L) 49 (38) 39 (SD 25) 63 (SD 64)
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